Landmark BioVentures AG
Overview
Landmark BioVentures AG is an integrated biotech hub-and-spoke company that operates as an entrepreneurial investment firm, co-founding and supporting a nexus of startups to develop first-in-class therapeutics.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Duhn Therapeutics | Oct 2024 | Strategic | Co-investor |
| Kekkan Biologics | - | Accelerator | Lead |
| Massalia Therapeutics | May 2025 | Seed | Lead |
| Elikya Therapeutics | - | Seed | Co-investor |
Key People
Gary Brandam
Co-founder and Chief Operating Officer
Mehdi Chelbi
Co-Founder
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Landmark BioVentures AG based?
Landmark BioVentures AG is headquartered in Basel, Switzerland.
When was Landmark BioVentures AG founded?
Landmark BioVentures AG was founded in 2021.
How many portfolio companies does Landmark BioVentures AG have?
Landmark BioVentures AG has 4 portfolio companies in Caplight's dataset.
What are some companies in Landmark BioVentures AG's portfolio?
Portfolio companies visible on Caplight include Duhn Therapeutics, Kekkan Biologics, Massalia Therapeutics, Elikya Therapeutics.
What was Landmark BioVentures AG's most recent investment shown here?
Landmark BioVentures AG's most recent investment in this portfolio sample was in Massalia Therapeutics in 2025.
What sectors does Landmark BioVentures AG focus on?
Landmark BioVentures AG focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Landmark BioVentures AG focus on?
Landmark BioVentures AG typically invests at the Early stage.